Categories: News

Spheryx Introduces xSight, a Revolutionary Particle Characterization Instrument, with Live Demonstrations at the 10th Annual PEGS Boston, April 8-12, 2019.

NEW YORK, April 4, 2019 /PRNewswire/ — Spheryx, Inc. will demonstrate xSight, their particle characterization instrument at PEGS Boston, April 8-12, 2019, in the Exhibit Hall at Seaport World Trade Center, Booth 500. PEGS Boston is the largest biologics event, drawing over 2,600 international participants interested in collaborating and sharing best practices in biologic therapeutics. xSight, uses Spheryx’s proprietary technology, Total Holographic Characterization®, to detect, count and characterize sub-visible particles in complex heterogeneous mixtures, including protein aggregates, a known safety hazard in biologic pharmaceuticals.

Additionally, Spheryx was selected from 4,500 applicants to participate in the Hello Tomorrow Global Summit in Paris, an annual competition to showcase start-ups that solve an unmet industrial, environmental or societal need.

Spheryx announces the addition of Dr. Ross Boltyanskiy in the roll of Senior Scientist. Dr. Boltyanskiy received his PhD in physics from Yale University, and was a Postdoctoral Research Fellow at Memorial Sloan Kettering. Dr. Laura Phillips, President and CEO, stated, “We are delighted to have Dr. Boltyanskiy on board. With his expertise in microscopy, opto-mechanical technology and data visualization, he is a welcome addition to the Spheryx team.”

About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization® of colloidal materials. Spheryx’s proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, offering unprecedented insights into these materials’ characteristics. Applications include R&D, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs. For more information: https://www.spheryx.solutions/

Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially.

Contact: Laura Philips, CEO
lphilips@spheryx.solutions  
607-738-0100

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/spheryx-introduces-xsight-a-revolutionary-particle-characterization-instrument-with-live-demonstrations-at-the-10th-annual-pegs-boston-april-8-12-2019-300824410.html

SOURCE Spheryx, Inc.

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

54 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

54 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

4 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

5 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

19 hours ago